-
Something wrong with this record ?
Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters
E. Mazzone, G. Gandaglia, D. Robesti, P. Rajwa, J. Gomez Rivas, L. Ibáñez, TFW. Soeterik, L. Bianchi, L. Afferi, C. Kesch, C. Darr, H. Guo, J. Zhuang, F. Zattoni, WP. Fendler, D. Amparore, NA. Huebner, A. Giesen, S. Joniau, R. Schiavina, E....
Language English Country Netherlands
Document type Journal Article
- MeSH
- Humans MeSH
- Lymphadenopathy * pathology surgery MeSH
- Lymphatic Metastasis pathology MeSH
- Lymph Nodes diagnostic imaging surgery pathology MeSH
- Magnetic Resonance Imaging MeSH
- Prostatic Neoplasms * diagnostic imaging surgery pathology MeSH
- Positron Emission Tomography Computed Tomography methods MeSH
- Positron-Emission Tomography MeSH
- Prostate diagnostic imaging surgery pathology MeSH
- Prostatectomy MeSH
- Prostate-Specific Antigen MeSH
- Seminal Vesicles pathology MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: The role of local therapies including radical prostatectomy (RP) in prostate cancer (PCa) patients with clinical lymphadenopathies on prostate-specific membrane antigen (PSMA) positron emission tomography/computerized tomography (PET/CT) has scarcely been explored. Limited data are available to identify men who would benefit from RP; on the contrary, those more likely to benefit already have systemic disease. OBJECTIVE: We aimed to assess the predictors of prostate-specific antigen (PSA) persistence in surgically managed PCa patients with lymphadenopathies on a PSMA PET/CT scan by integrating clinical, magnetic resonance imaging (MRI), and PSMA PET/CT parameters. DESIGN, SETTING, AND PARTICIPANTS: We identified 519 patients treated with RP and extended lymph node dissection, and who received preoperative PSMA PET between 2017 and 2022 in nine referral centers. Among them, we selected 88 patients with nodal uptake at preoperative PSMA PET (miTxN1M0). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcome was PSA persistence, defined as a PSA value of ≥0.1 ng/ml at the first measurement after surgery. Multivariable logistic regression models tested the predictors of PSA persistence. Covariates consisted of biopsy International Society of Urological Pathology (ISUP) grade group, clinical stage at MRI, and number of positive spots at a PET/CT scan. A regression tree analysis stratified patients into risk groups based on preoperative characteristics. RESULTS AND LIMITATIONS: Overall, lymph node invasion (LNI) was detected in 63 patients (72%) and 32 (36%) experienced PSA persistence after RP. At multivariable analyses, having more than two lymph nodal positive findings at PSMA PET, seminal vesicle invasion (SVI) at MRI, and ISUP grade group >3 at biopsy were independent predictors of PSA persistence (all p < 0.05). At the regression tree analysis, patients were stratified in four risk groups according to biopsy ISUP grade, number of positive findings at PET/CT, and clinical stage at MRI. The model depicted good discrimination at internal validation (area under the curve 78%). CONCLUSIONS: One out of three miN1M0 patients showed PSA persistence after surgery. Patients with ISUP grade 2-3, as well as patients with organ-confined disease at MRI and a single or two positive nodal findings at PET are those in whom RP may achieve the best oncological outcomes in the context of a multimodal approach. Conversely, patients with a high ISUP grade and extracapsular extension or SVI or more than two spots at PSMA PET should be considered as potentially affected by systemic disease upfront. PATIENT SUMMARY: Our novel and straightforward risk classification integrates currently available preoperative risk tools and should, therefore, assist physician in preoperative counseling of men candidates for radical treatment for prostate cancer with positive lymph node uptake at prostate-specific membrane antigen positron emission tomography.
Department of Nuclear Medicine IRCCS Ospedale San Raffaele Milan Italy
Department of Nuclear Medicine University of Duisburg Essen Germany
Department of Oncology Division of Urology San Luigi Gonzaga Hospital Turin Italy
Department of Radiation Oncology University Medical Center Utrecht The Netherlands
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Hospital Clinico San Carlos Madrid Spain
Department of Urology Luzerner Kantonsspital Luzern Switzerland
Department of Urology Medical University of Silesia Zabrze Poland
Department of Urology Medical University of Vienna Vienna Austria
Department of Urology St Antonius Hospital Utrecht The Netherlands
Department of Urology University Hospitals Leuven Leuven Belgium
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Department of Urology West German Cancer Center University of Duisburg Essen Germany
Department Surgery Oncology and Gastroenterology Urologic Unit University of Padova Padua Italy
Division of Urology Department of Special Surgery The University of Jordan Amman Jordan
Division of Urology IRCCS Azienda Ospedaliero Universitaria di Bologna Bologna Italy
German Cancer Consortium University Hospital Essen Essen Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006628
- 003
- CZ-PrNML
- 005
- 20240423155417.0
- 007
- ta
- 008
- 240412s2024 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.euo.2023.08.010 $2 doi
- 035 __
- $a (PubMed)37689506
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Mazzone, Elio $u Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address: mazzone.elio@hsr.it
- 245 10
- $a Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters / $c E. Mazzone, G. Gandaglia, D. Robesti, P. Rajwa, J. Gomez Rivas, L. Ibáñez, TFW. Soeterik, L. Bianchi, L. Afferi, C. Kesch, C. Darr, H. Guo, J. Zhuang, F. Zattoni, WP. Fendler, D. Amparore, NA. Huebner, A. Giesen, S. Joniau, R. Schiavina, E. Brunocilla, A. Mattei, F. Dal Moro, J. Moreno Sierra, F. Porpiglia, M. Picchio, A. Chiti, R. van den Bergh, SF. Shariat, F. Montorsi, A. Briganti
- 520 9_
- $a BACKGROUND: The role of local therapies including radical prostatectomy (RP) in prostate cancer (PCa) patients with clinical lymphadenopathies on prostate-specific membrane antigen (PSMA) positron emission tomography/computerized tomography (PET/CT) has scarcely been explored. Limited data are available to identify men who would benefit from RP; on the contrary, those more likely to benefit already have systemic disease. OBJECTIVE: We aimed to assess the predictors of prostate-specific antigen (PSA) persistence in surgically managed PCa patients with lymphadenopathies on a PSMA PET/CT scan by integrating clinical, magnetic resonance imaging (MRI), and PSMA PET/CT parameters. DESIGN, SETTING, AND PARTICIPANTS: We identified 519 patients treated with RP and extended lymph node dissection, and who received preoperative PSMA PET between 2017 and 2022 in nine referral centers. Among them, we selected 88 patients with nodal uptake at preoperative PSMA PET (miTxN1M0). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcome was PSA persistence, defined as a PSA value of ≥0.1 ng/ml at the first measurement after surgery. Multivariable logistic regression models tested the predictors of PSA persistence. Covariates consisted of biopsy International Society of Urological Pathology (ISUP) grade group, clinical stage at MRI, and number of positive spots at a PET/CT scan. A regression tree analysis stratified patients into risk groups based on preoperative characteristics. RESULTS AND LIMITATIONS: Overall, lymph node invasion (LNI) was detected in 63 patients (72%) and 32 (36%) experienced PSA persistence after RP. At multivariable analyses, having more than two lymph nodal positive findings at PSMA PET, seminal vesicle invasion (SVI) at MRI, and ISUP grade group >3 at biopsy were independent predictors of PSA persistence (all p < 0.05). At the regression tree analysis, patients were stratified in four risk groups according to biopsy ISUP grade, number of positive findings at PET/CT, and clinical stage at MRI. The model depicted good discrimination at internal validation (area under the curve 78%). CONCLUSIONS: One out of three miN1M0 patients showed PSA persistence after surgery. Patients with ISUP grade 2-3, as well as patients with organ-confined disease at MRI and a single or two positive nodal findings at PET are those in whom RP may achieve the best oncological outcomes in the context of a multimodal approach. Conversely, patients with a high ISUP grade and extracapsular extension or SVI or more than two spots at PSMA PET should be considered as potentially affected by systemic disease upfront. PATIENT SUMMARY: Our novel and straightforward risk classification integrates currently available preoperative risk tools and should, therefore, assist physician in preoperative counseling of men candidates for radical treatment for prostate cancer with positive lymph node uptake at prostate-specific membrane antigen positron emission tomography.
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a prostatický specifický antigen $7 D017430
- 650 _2
- $a prostata $x diagnostické zobrazování $x chirurgie $x patologie $7 D011467
- 650 _2
- $a PET/CT $x metody $7 D000072078
- 650 _2
- $a semenné váčky $x patologie $7 D012669
- 650 _2
- $a lymfatické metastázy $x patologie $7 D008207
- 650 12
- $a nádory prostaty $x diagnostické zobrazování $x chirurgie $x patologie $7 D011471
- 650 _2
- $a lymfatické uzliny $x diagnostické zobrazování $x chirurgie $x patologie $7 D008198
- 650 _2
- $a prostatektomie $7 D011468
- 650 _2
- $a pozitronová emisní tomografie $7 D049268
- 650 _2
- $a magnetická rezonanční tomografie $7 D008279
- 650 12
- $a lymfadenopatie $x patologie $x chirurgie $7 D000072281
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Gandaglia, Giorgio $u Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
- 700 1_
- $a Robesti, Daniele $u Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
- 700 1_
- $a Rajwa, Pawel $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Medical University of Silesia, Zabrze, Poland
- 700 1_
- $a Gomez Rivas, Juan $u Department of Urology, Hospital Clinico San Carlos, Madrid, Spain
- 700 1_
- $a Ibáñez, Laura $u Department of Urology, Hospital Clinico San Carlos, Madrid, Spain
- 700 1_
- $a Soeterik, Timo F W $u Department of Urology, St Antonius Hospital, Utrecht, The Netherlands; Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands
- 700 1_
- $a Bianchi, Lorenzo $u Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- 700 1_
- $a Afferi, Luca $u Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland
- 700 1_
- $a Kesch, Claudia $u Department of Urology, West German Cancer Center, University of Duisburg, Essen, Germany; German Cancer Consortium, University Hospital Essen, Essen, Germany
- 700 1_
- $a Darr, Christopher $u Department of Urology, West German Cancer Center, University of Duisburg, Essen, Germany; German Cancer Consortium, University Hospital Essen, Essen, Germany
- 700 1_
- $a Guo, Hongqian $u Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Jiangsu, China
- 700 1_
- $a Zhuang, Junlong $u Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Jiangsu, China
- 700 1_
- $a Zattoni, Fabio $u Department Surgery, Oncology and Gastroenterology, Urologic Unit, University of Padova, Padua, Italy
- 700 1_
- $a Fendler, Wolfgang P $u German Cancer Consortium, University Hospital Essen, Essen, Germany; Department of Nuclear Medicine, University of Duisburg, Essen, Germany
- 700 1_
- $a Amparore, Daniele $u Department of Oncology, Division of Urology, San Luigi Gonzaga Hospital, Turin, Italy
- 700 1_
- $a Huebner, Nicolai A $u Department of Urology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Giesen, Alexander $u Department of Urology, University Hospitals Leuven, Leuven, Belgium
- 700 1_
- $a Joniau, Steven $u Department of Urology, University Hospitals Leuven, Leuven, Belgium
- 700 1_
- $a Schiavina, Riccardo $u Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- 700 1_
- $a Brunocilla, Eugenio $u Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- 700 1_
- $a Mattei, Agostino $u Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland
- 700 1_
- $a Dal Moro, Fabrizio $u Department Surgery, Oncology and Gastroenterology, Urologic Unit, University of Padova, Padua, Italy
- 700 1_
- $a Moreno Sierra, Jesus $u Department of Urology, Hospital Clinico San Carlos, Madrid, Spain
- 700 1_
- $a Porpiglia, Francesco $u Department of Oncology, Division of Urology, San Luigi Gonzaga Hospital, Turin, Italy
- 700 1_
- $a Picchio, Maria $u Vita-Salute San Raffaele University, Milan, Italy; Department of Nuclear Medicine, IRCCS Ospedale San Raffaele, Milan, Italy
- 700 1_
- $a Chiti, Arturo $u Vita-Salute San Raffaele University, Milan, Italy; Department of Nuclear Medicine, IRCCS Ospedale San Raffaele, Milan, Italy
- 700 1_
- $a van den Bergh, Roderick $u Department of Urology, St Antonius Hospital, Utrecht, The Netherlands
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan
- 700 1_
- $a Montorsi, Francesco $u Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
- 700 1_
- $a Briganti, Alberto $u Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
- 773 0_
- $w MED00205913 $t European urology oncology $x 2588-9311 $g Roč. 7, č. 2 (2024), s. 231-240
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37689506 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155414 $b ABA008
- 999 __
- $a ok $b bmc $g 2080939 $s 1216395
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 7 $c 2 $d 231-240 $e 20230909 $i 2588-9311 $m European urology oncology $n Eur Urol Oncol $x MED00205913
- LZP __
- $a Pubmed-20240412
